- InterView
- “Korea is fully capable of developing new microbiome drugs"
- by Nho, Byung Chul Nov 18, 2022 06:04am
- “The development of metagenomics technology that extracts DNA directly from samples without culturing in 1998 enabled the field of human microbiome research to make a giant leap forward. The success and failure of innovative new microbiome-based therapeutics depend on identifying, standardizing, and materializing the keystone species in the
- InterView
- “Amgen addresses all unmet needs regardless of indication”
- by Eo, Yun-Ho Nov 17, 2022 05:54am
- Amgen owns a vast portfolio of treatments in many areas. Rather than focusing on a particular field, the company has been known to release new drugs in the right places at the right time In addition to actively developing drugs for chronic diseases such as the osteoporosis treatments 'Prolia (denosumab)’ and ‘Evenity (romosozumab),’ t
- InterView
- “BMS makes the next leap with its solid pipeline”
- by Eo, Yun-Ho Oct 31, 2022 06:06am
- Mergers have become one of the main survival strategies for global multinational pharmaceutical companies. In addition to buying new substances, companies are also making synergy, absorbing companies that own pipelines with high potential. BMS is one representative example of such successful mergers. When the power of its portfolio decli
- InterView
- "Lilly rises in anticancer and autoimmune diseases"
- by Eo, Yun-Ho Oct 27, 2022 05:52am
- The pharmaceutical company Lilly is known for their strong diabetes treatment pipeline. As the world’s first developer of insulin, Lilly has solidified its position in the field, introducing DPP-4 inhibitors, SGLT-2 inhibitors, and GLP-1 analogues into its pipeline. However, Lilly has transformed. It did not give up diabetes, the company
- InterView
- “AstraZeneca’s sincerity in oncology drives cont. growth"
- by Eo, Yun-Ho Oct 17, 2022 06:03am
- AstraZeneca is known for its ‘sincere attitude’ towards R&D. Not only is the company in the top ranks in terms of its investment amount, but it has also always been at the forefront in terms of R&D-to-Total-revenue ratio as well. In 2021, AstraZeneca’s R&D-to-Total-revenue ratio stood at 26%, the highest in the industry. Due to their i
- InterView
- “Sanofi’s flu vaccine is different...has 100-year legacy"
- by Oct 6, 2022 06:05am
- Sanofi has been making unexpected strides in Korea's flu (influenza) vaccine market this year. The company has not only made a bid for the National Immunization Program (NIP) for the first time this year, but it also started supplying its flu vaccines exceptionally quickly. Multinational pharmaceutical companies usually start the supply of their
- InterView
- “Will rise independently as Organon in the industry”
- by Eo, Yun-Ho Sep 8, 2022 05:59am
- Spin-offs, which are made for various reasons in various circumstances, bring out various positive and negative issues in the process. Organon’s course of the spin-off was also quite eventful. However, the company quickly straightened its affairs after completing the spin-off and being reborn as an independent organization in June last y
- InterView
- "Leclaza’s mOS data of 38.9 months is remarkable"
- by Kim, Jin-Gu Jul 4, 2022 05:55am
- “The fact that Leclaza (lasertinib) achieved an OS (overall survival) of over 3 years is remarkable.” New OS data on the homegrown novel lung cancer drug Leclaza that was presented at the AOS 2022 & KCA Annual Meeting 2022 that was held recently in Seoul drew the pharmaceutical industry's attention. The results were from a trial that eva
- InterView
- Tremfya to bring generation shift in the IL inhibitor market
- by Jun 23, 2022 05:50am
- The competition among latecomers is intensifying in the interleukin inhibitor market with the scope of their indications expanding to psoriatic arthritis. The leader in this market is Janssen’s IL-12/23 inhibitor, ‘Stelara (Ustekinumab).’ Although 10 years have passed since its approval, the drug still boasts a growth rate in the 30% range
- InterView
- “Roche reborn through customer-centric reorganization”
- by Eo, Yun-Ho Jun 21, 2022 05:54am
- Multinational pharmaceutical companies are known to endlessly pursue change. In addition to active acquisitions, mergers, and spin-offs, the companies boldly reduce and expand their many originations in line with the new drug development trend, and show no hesitation in consolidating or reorganizing departments. Their endless evolution for e
